Peri-Strips Dry With Secure Grip Technology for Reliable Staple Line Reinforcement in Surgical Procedures Launched

Baxter International Reports Peri-Strips Dry with Veritas Collagen Matrix (PSDV) Product known as PSDV with Secure Grip Receives FDA Clearance

Wil Boren, president of Baxter’s Advanced Surgery business said, “We continue to advance innovation by providing surgeons tools that are faster and easier to use in the operating room.”  He added, “As surgical procedures are becoming more complex, it is important that surgeons have the tools they need to optimize patient care.”

Despite the sophistication of modern stapling technology used in bariatric procedures, staple line complications that result in high morbidity and mortality persist. The most prevalent complications are staple line bleeding and leaks. While the incidence of these complications is low, the impact can be clinically debilitating for the patient and costly to address.2

Peri-Strips Dry With Secure Grip Technology (PSDV) is proven to effectively reduce intraoperative and postoperative staple line bleeds and leaks in routine bariatric procedures such as a sleeve gastrectomy or gastric bypass. A 2015 meta-analysis extracted data from 295 studies predominantly comprised of morbidly obese patients undergoing laparoscopic gastric bypass and laparoscopic sleeve gastrectomy to include nearly 42,000 patients concerning bleeds and over 56,000 patients concerning leaks. PSDV showed statistically significant greater relative efficacy in reducing bleeding and leaks when compared to no staple line reinforcement, oversewing, and another staple line reinforcement product.2

PSDV with Secure Grip is applied to the surgical stapler via a pressure-sensitive adhesive strip. The new generation of PSDV provides strong adherence to the stapler, allowing surgeons to easily manipulate tissue. In a recent Staple Line Reinforcement Comparison study,1 30 bariatric nurses and surgical technicians evaluated stapler preparation time, ease of use and learnability of the PSDV with Secure Grip versus other options. Participants unanimously chose PSDV with Secure Grip as the most preferred staple line reinforcement material in the operating room.

PSDV with Secure Grip is available now to Baxter customers.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version